Medipost
Rockville, United States· Est.
A commercial-stage company developing allogeneic cord blood-derived stem cell therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $140M
AI Company Overview
A commercial-stage company developing allogeneic cord blood-derived stem cell therapies.
Regenerative MedicineOrthopedics
Technology Platform
Proprietary platform for manufacturing allogeneic, off-the-shelf mesenchymal stem cell therapies from umbilical cord blood.
Funding History
1Total raised:$140M
IPO$140M
Opportunities
Leveraging its commercial experience and platform to expand into new, large-market degenerative diseases.
Risk Factors
Regulatory and market access hurdles for expansion into new geographic regions like the US and EU.
Competitive Landscape
Competes with other MSC therapy companies (e.g., Mesoblast) and emerging gene-modified cell therapies in regenerative medicine.